Bio-Rad Laboratories (BIO) EBT (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported EBT for 18 consecutive years, with $542.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 30.94% year-over-year to $542.1 million in Q2 2026; TTM through Jun 2026 was $350.4 million, a 22.15% decrease from a year earlier, with the FY2025 full-year figure at $995.5 million, up 142.5% from the prior year.
• EBT was $542.1 million for Q2 2026 at Bio-Rad Laboratories, up from -$689.8 million in the prior quarter.
• Over five years, EBT peaked at $1.1 billion in Q4 2022 and troughed at -$4.4 billion in Q1 2022.
• A 5-year average of -$391.6 million and a median of $84.1 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT jumped 528.44% in 2024 and slumped 927.1% in 2026, its largest moves.
• Over 5 years, EBT stood at $1.1 billion in 2022, then slumped by 60.75% to $428.4 million in 2023, then plunged by 312.16% to -$908.9 million in 2024, then jumped by 202.23% to $929.2 million in 2025, then slumped by 41.66% to $542.1 million in 2026.
• The last three EBT figures came in at $542.1 million (Q2 2026), -$689.8 million (Q1 2026), and $929.2 million (Q4 2025), per Business Quant data.